| Juvenile polyarthritis
Simponi ARIA vs Xatmep
Side-by-side clinical, coverage, and cost comparison for juvenile polyarthritis.Deep comparison between: Simponi Aria vs Xatmep with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXatmep has a higher rate of injection site reactions vs Simponi Aria based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xatmep but not Simponi Aria, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Simponi Aria
Xatmep
At A Glance
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Oral
Once weekly
Folate analog metabolic inhibitor
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Juvenile polyarthritis
- Acute lymphocytic leukemia
- Juvenile polyarthritis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter; RA patients must receive concomitant methotrexate.
Juvenile polyarthritis 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter (body surface area-based dosing for patients 2 years of age and older).
Acute lymphocytic leukemia 20 mg/m2 given one time weekly as part of a multi-agent combination chemotherapy maintenance regimen, oral.
Juvenile polyarthritis Starting dose of 10 mg/m2 given one time weekly, oral; titrate gradually to achieve optimal response, up to 30 mg/m2/week in pediatric patients.
Contraindications
—
- Pregnancy in patients with non-malignant diseases
- Severe hypersensitivity to methotrexate
Adverse Reactions
Most common (>=1%) Upper respiratory tract infection, viral infections, bacterial infections, bronchitis, hypertension, rash, pyrexia, leukopenia
Serious Serious infections (sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis), malignancies, liver enzyme elevations, infusion reactions
Postmarketing Infusion-related reactions, melanoma, Merkel cell carcinoma, anaphylactic reaction, sarcoidosis, interstitial lung disease, skin exfoliation, lichenoid reactions, bullous skin reactions
Most common Ulcerative stomatitis, leukopenia, nausea, abdominal distress, malaise, fatigue, chills, fever, dizziness, decreased resistance to infection
Serious Bone marrow suppression, serious infections, renal toxicity, gastrointestinal toxicity, hepatic toxicity, pulmonary toxicity, hypersensitivity and dermatologic reactions, secondary malignancies, infertility
Postmarketing Pancytopenia, aplastic anemia, thromboembolic events, hepatotoxicity, cirrhosis, fatal opportunistic infections (including Pneumocystis jiroveci pneumonia), leukoencephalopathy, Stevens-Johnson syndrome, toxic epidermal necrolysis, pulmonary fibrosis
Pharmacology
Golimumab is a human monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing receptor binding and inhibiting TNF-alpha biological activity, a key mediator of articular inflammation in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Methotrexate inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication by blocking reduction of dihydrofolates to tetrahydrofolates required for purine nucleotide and thymidylate synthesis; the mechanism in pJIA is unknown but may affect immune function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Simponi Aria
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Xatmep
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (2/12) · Qty limit (0/12)
UnitedHealthcare
Simponi Aria
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (3/8)
Xatmep
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Simponi Aria
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Xatmep
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Xatmep.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Simponi AriaView full Simponi Aria profile
XatmepView full Xatmep profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.